tetano
Editor, Senior Moderator
Arch Pharm Res
. 2021 Jan 4.
doi: 10.1007/s12272-020-01301-7. Online ahead of print.
Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective
Choongho Lee[SUP] 1 [/SUP], Won Jun Choi[SUP] 2 [/SUP]
Affiliations
Abstract
The novel beta coronavirus (SARS-CoV-2, designated as COVID-19) that is responsible for severe acute respiratory syndrome has devastated the global economy and health care system. Since COVID-19 changed the definition of "normal" in ordinary life around the world, the development of effective therapeutics and preventive measures is desperately needed to fight SARS-CoV-2 infection and restore normalcy. A clear understanding of COVID-19 pathogenesis is crucial in providing the scientific rationale necessary to develop anti-COVID19 drugs and vaccines. According to the most recently published literature, COVID-19 pathogenesis was postulated to occur in three sequential phases: pulmonary, proinflammatory, and prothrombic. Herein, virus-host interactions, potential pathogenic mechanisms, and clinical manifestations are described for each phase. Additionally, based on this pathogenesis model, various therapeutic strategies involving current clinical trials are presented with an explanation of their modes of action and example drugs. This review is a thorough, updated summary of COVID-19 pathogenesis and the therapeutic options available for this disease.
Keywords: ACE2 deficiency; Acute lung injury (ALI); Acute respiratory distress syndrome (ARDS); Angiotensin-converting enzyme 2 (ACE2); Coagulopathy; Coronavirus disease 2019 (COVID-19); Cytokine storm; Multi-organ failure (MOF); Renin-angiotensin system (RAS); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Thrombosis.
. 2021 Jan 4.
doi: 10.1007/s12272-020-01301-7. Online ahead of print.
Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective
Choongho Lee[SUP] 1 [/SUP], Won Jun Choi[SUP] 2 [/SUP]
Affiliations
- PMID: 33398692
- DOI: 10.1007/s12272-020-01301-7
Abstract
The novel beta coronavirus (SARS-CoV-2, designated as COVID-19) that is responsible for severe acute respiratory syndrome has devastated the global economy and health care system. Since COVID-19 changed the definition of "normal" in ordinary life around the world, the development of effective therapeutics and preventive measures is desperately needed to fight SARS-CoV-2 infection and restore normalcy. A clear understanding of COVID-19 pathogenesis is crucial in providing the scientific rationale necessary to develop anti-COVID19 drugs and vaccines. According to the most recently published literature, COVID-19 pathogenesis was postulated to occur in three sequential phases: pulmonary, proinflammatory, and prothrombic. Herein, virus-host interactions, potential pathogenic mechanisms, and clinical manifestations are described for each phase. Additionally, based on this pathogenesis model, various therapeutic strategies involving current clinical trials are presented with an explanation of their modes of action and example drugs. This review is a thorough, updated summary of COVID-19 pathogenesis and the therapeutic options available for this disease.
Keywords: ACE2 deficiency; Acute lung injury (ALI); Acute respiratory distress syndrome (ARDS); Angiotensin-converting enzyme 2 (ACE2); Coagulopathy; Coronavirus disease 2019 (COVID-19); Cytokine storm; Multi-organ failure (MOF); Renin-angiotensin system (RAS); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Thrombosis.